Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC OncLive 2:56 1 month ago 69 Далее Скачать
Patient Selection for IO/IO Versus IO/TKI in the Frontline Setting GU Oncology Now 7:57 1 year ago 166 Далее Скачать
IO-IO and IO-TKI treatments could improve 5-year survival rate for aRCC VJOncology 0:34 1 year ago 66 Далее Скачать
Frontline RCC Treatment Selection: IO/IO Versus IO/TKI GU Oncology Now 9:16 10 months ago 316 Далее Скачать
IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment GU Oncology Now 6:15 2 months ago 42 Далее Скачать
Myth Busted: Should all PD-L1 positive mNSCLC patients receive IO first? EGFRmNSCLC 3:05 4 years ago 60 006 Далее Скачать
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC GU Oncology Now 6:45 10 months ago 94 Далее Скачать
Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and More GU Oncology Now 8:15 1 year ago 228 Далее Скачать
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC OncLive 1:50 1 month ago 58 Далее Скачать
